Blog

Nov 5, 2019

Israeli team develops novel therapy to target advanced cancerous tumors

Posted by in categories: biotech/medical, innovation

Holon-based cancer immunotherapy company Compugen disclosed encouraging preliminary results on Tuesday from its Phase 1 clinical trial for an antibody acting against a novel cancer drug target (PVRIG) in patients with advanced solid tumors.

The Nasdaq and Tel Aviv-listed company, a pioneer in predictive drug target discovery, has developed innovative computational discovery platforms to identify new drug targets and subsequently produce first-in-class therapeutics. The clinical trial of the anti-PVRIG antibody, called COM701, aimed to assess the safety of escalating doses of the therapy in patients with advanced solid tumors, but also demonstrated initial signals of anti-tumor activity in the heavily pre-treated patient population enrolled in the study.

“We are encouraged by the emerging safety profile and initial signals of anti-tumor activity of COM701,” said Compugen president and CEO Dr. Anat Cohen-Dayan.

1

Comment so far

  • Appliance Repair on November 5, 2019 7:39 am

    If this actually comes to fruition it would mean recovering and quality of life for so many people. One can continue to hope. Wonderful article!

Leave a reply